Kainova Therapeutics
Kainova Therapeutics is a Healthcare & Life Sciences startup based in Canada, most recent round Series B, 1 tracked investor.
About Kainova Therapeutics
Kainova Therapeutics is a company headquartered in Canada. Its most recent tracked round is Series B. Brouky classifies it under Healthcare & Life Sciences. Brouky records 1 investor associated with the company.
Kainova Therapeutics is a clinical-stage company developing therapies that target G protein-coupled receptors (GPCRs) for immuno-oncology and inflammatory diseases. Its lead programs include DT-7012 (an anti-CCR8 Treg-depleting antibody), DT-9046 (a preclinical biased PAR2 antagonist), and DT-9081 (a Phase II-ready EP4 receptor antagonist for solid tumors).
Explore Kainova Therapeutics's full profile on Brouky
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.